950 related articles for article (PubMed ID: 16831265)
21. Prospective validation of serum CYFRA 21-1, beta-2-microglobulin, and ferritin levels as prognostic markers in patients with nonmetastatic nasopharyngeal carcinoma undergoing radiotherapy.
Ma BB; Leungm SF; Hui EP; Mo F; Kwan WH; Zee B; Yuen J; Chan AT
Cancer; 2004 Aug; 101(4):776-81. PubMed ID: 15305409
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of plasma Epstein-Barr virus DNA load as a prognostic marker for nasopharyngeal carcinoma.
Tan EL; Looi LM; Sam CK
Singapore Med J; 2006 Sep; 47(9):803-7. PubMed ID: 16924363
[TBL] [Abstract][Full Text] [Related]
23. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma.
Leung SF; Zee B; Ma BB; Hui EP; Mo F; Lai M; Chan KC; Chan LY; Kwan WH; Lo YM; Chan AT
J Clin Oncol; 2006 Dec; 24(34):5414-8. PubMed ID: 17135642
[TBL] [Abstract][Full Text] [Related]
24. [Correlation of DNA ploidy in fresh tumor tissues to prognosis of nasopharyngeal carcinoma].
Han F; Wang HY; Xia YF; Liu MZ; Zhao C; Lu TX
Ai Zheng; 2007 Sep; 26(9):1015-9. PubMed ID: 17927864
[TBL] [Abstract][Full Text] [Related]
25. A comparison study of different PCR assays in measuring circulating plasma epstein-barr virus DNA levels in patients with nasopharyngeal carcinoma.
Le QT; Jones CD; Yau TK; Shirazi HA; Wong PH; Thomas EN; Patterson BK; Lee AW; Zehnder JL
Clin Cancer Res; 2005 Aug; 11(16):5700-7. PubMed ID: 16115906
[TBL] [Abstract][Full Text] [Related]
26. Plasma Epstein-Barr virus DNA screening followed by ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma.
Wang WY; Twu CW; Lin WY; Jiang RS; Liang KL; Chen KW; Wu CT; Shih YT; Lin JC
Cancer; 2011 Oct; 117(19):4452-9. PubMed ID: 21437892
[TBL] [Abstract][Full Text] [Related]
27. Non-metastatic stage IV nasopharyngeal carcinoma patients: analysis of the pattern of relapse and survival.
Ozyar E; Gurkaynak M; Yildiz F; Atahan IL
Radiother Oncol; 2004 Jul; 72(1):71-7. PubMed ID: 15236877
[TBL] [Abstract][Full Text] [Related]
28. [The clinical value of quantitative analysis of plasma Epstein-Barr virus DNA in patients with nasopharyngeal carcinoma].
Yuan H; Yang BB; Xu ZF
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2004 Mar; 39(3):162-5. PubMed ID: 15283296
[TBL] [Abstract][Full Text] [Related]
29. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma.
Lo YM; Chan LY; Chan AT; Leung SF; Lo KW; Zhang J; Lee JC; Hjelm NM; Johnson PJ; Huang DP
Cancer Res; 1999 Nov; 59(21):5452-5. PubMed ID: 10554016
[TBL] [Abstract][Full Text] [Related]
30. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
[TBL] [Abstract][Full Text] [Related]
31. Disparity of sensitivities in detection of radiation-naïve and postirradiation recurrent nasopharyngeal carcinoma of the undifferentiated type by quantitative analysis of circulating Epstein-Barr virus DNA1,2.
Leung SF; Lo YM; Chan AT; To KF; To E; Chan LY; Zee B; Huang DP; Johnson PJ
Clin Cancer Res; 2003 Aug; 9(9):3431-4. PubMed ID: 12960133
[TBL] [Abstract][Full Text] [Related]
32. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma.
Chan AT; Lo YM; Zee B; Chan LY; Ma BB; Leung SF; Mo F; Lai M; Ho S; Huang DP; Johnson PJ
J Natl Cancer Inst; 2002 Nov; 94(21):1614-9. PubMed ID: 12419787
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of paranasopharyngeal extension of nasopharyngeal carcinoma. A significant factor in local control and distant metastasis.
Chua DT; Sham JS; Kwong DL; Choy DT; Au GK; Wu PM
Cancer; 1996 Jul; 78(2):202-10. PubMed ID: 8673993
[TBL] [Abstract][Full Text] [Related]
34. Quantitative analysis of the transrenal excretion of circulating EBV DNA in nasopharyngeal carcinoma patients.
Chan KC; Leung SF; Yeung SW; Chan AT; Lo YM
Clin Cancer Res; 2008 Aug; 14(15):4809-13. PubMed ID: 18676752
[TBL] [Abstract][Full Text] [Related]
35. The prognostic influence of prevertebral space involvement in nasopharyngeal carcinoma.
Lee CC; Chu ST; Chou P; Lee CC; Chen LF
Clin Otolaryngol; 2008 Oct; 33(5):442-9. PubMed ID: 18983377
[TBL] [Abstract][Full Text] [Related]
36. Epstein-Barr virus DNA quantification and follow-up in Tunisian nasopharyngeal carcinoma patients.
Hassen E; Farhat K; Gabbouj S; Bouaouina N; Abdelaziz H; Chouchane L
Biomarkers; 2011 May; 16(3):274-80. PubMed ID: 21506698
[TBL] [Abstract][Full Text] [Related]
37. Outpatient weekly 24-hour infusional adjuvant chemotherapy of cisplatin, 5-fluorouracil, and leucovorin for high-risk nasopharyngeal carcinoma.
Lin JC; Jan JS; Chen KY; Hsu CY; Liang WM; Wang WY
Head Neck; 2003 Jun; 25(6):438-50. PubMed ID: 12784235
[TBL] [Abstract][Full Text] [Related]
38. Prognostic implication of pretreatment titer of serum immunoglobulin A against Epstein-Barr virus capsid antigen in nasopharyngeal carcinoma patients in Sihui, Guangdong.
Ling W; Cao SM; Huang QH; Li YH; Deng MQ
Ai Zheng; 2009 Jan; 28(1):57-9. PubMed ID: 19448418
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA.
Chan AT; Ma BB; Lo YM; Leung SF; Kwan WH; Hui EP; Mok TS; Kam M; Chan LS; Chiu SK; Yu KH; Cheung KY; Lai K; Lai M; Mo F; Yeo W; King A; Johnson PJ; Teo PM; Zee B
J Clin Oncol; 2004 Aug; 22(15):3053-60. PubMed ID: 15284255
[TBL] [Abstract][Full Text] [Related]
40. Combined determination of Epstein-Barr virus-related antibodies and antigens for diagnosis of nasopharyngeal carcinoma.
Luo YL; Ou GP; Chi PD; Liang YN; Liu YH; Huang MY
Ai Zheng; 2009 Jan; 28(1):76-8. PubMed ID: 19448423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
